603590 康辰药业
交易中 12-18 14:08:55
资讯
新帖
简况
康辰药业拟取消监事会并修订公司章程,将召开股东大会审议多项议案
中金财经 · 12-16 08:22
康辰药业拟取消监事会并修订公司章程,将召开股东大会审议多项议案
康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组
智通财经 · 12-15 20:05
康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组
异动快报:康辰药业(603590)12月3日13点13分触及涨停板
证券之星 · 12-03
异动快报:康辰药业(603590)12月3日13点13分触及涨停板
康辰药业(603590)披露召开2025年第三季度业绩说明会,11月26日股价下跌1.28%
证券之星 · 11-26
康辰药业(603590)披露召开2025年第三季度业绩说明会,11月26日股价下跌1.28%
每周股票复盘:康辰药业(603590)董事减持3%股份,公司回购39.74万股
证券之星 · 11-09
每周股票复盘:康辰药业(603590)董事减持3%股份,公司回购39.74万股
康辰药业已回购40万股 金额2016万元
财中社 · 11-05
康辰药业已回购40万股 金额2016万元
太平洋:给予康辰药业买入评级
证券之星 · 11-05
太平洋:给予康辰药业买入评级
11月4日康辰药业跌6.45%,前海开源医疗健康A基金重仓该股
证券之星 · 11-04
11月4日康辰药业跌6.45%,前海开源医疗健康A基金重仓该股
康辰药业:10月31日高管刘建华减持股份合计53.12万股
证券之星 · 11-03
康辰药业:10月31日高管刘建华减持股份合计53.12万股
每周股票复盘:康辰药业(603590)三季报扣非净利增25.9%
证券之星 · 11-02
每周股票复盘:康辰药业(603590)三季报扣非净利增25.9%
康辰药业(603590)2025年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 10-31
康辰药业(603590)2025年三季报简析:营收净利润同比双双增长,盈利能力上升
康辰药业(603590.SH)发布前三季度业绩,归母净利润1.28亿元,同比增长13.19%
智通财经 · 10-30
康辰药业(603590.SH)发布前三季度业绩,归母净利润1.28亿元,同比增长13.19%
康辰药业(603590)9月30日股东户数1.07万户,较上期增加7.18%
证券之星 · 10-29
康辰药业(603590)9月30日股东户数1.07万户,较上期增加7.18%
每周股票复盘:康辰药业(603590)董事减持近千万股且回购首秀耗资1915万
证券之星 · 10-26
每周股票复盘:康辰药业(603590)董事减持近千万股且回购首秀耗资1915万
10月24日康辰药业现1笔折价10.37%的大宗交易 合计成交203.93万元
证券之星 · 10-24
10月24日康辰药业现1笔折价10.37%的大宗交易 合计成交203.93万元
康辰药业:10月20日高管刘建华减持股份合计191.19万股
证券之星 · 10-22
康辰药业:10月20日高管刘建华减持股份合计191.19万股
康辰药业:10月17日高管刘建华减持股份合计102.15万股
证券之星 · 10-21
康辰药业:10月17日高管刘建华减持股份合计102.15万股
10月20日康辰药业现16笔折价13.46%的大宗交易 合计成交4473.87万元
证券之星 · 10-20
10月20日康辰药业现16笔折价13.46%的大宗交易 合计成交4473.87万元
每周股票复盘:康辰药业(603590)推5000万至1亿元回购计划
证券之星 · 10-19
每周股票复盘:康辰药业(603590)推5000万至1亿元回购计划
10月17日康辰药业现1494.57万元大宗交易
证券之星 · 10-17
10月17日康辰药业现1494.57万元大宗交易
加载更多
公司概况
公司名称:
北京康辰药业股份有限公司
所属行业:
医药制造业
上市日期:
2018-08-27
主营业务:
北京康辰药业股份有限公司的主营业务是化学药品制剂制造。公司的主要产品是“苏灵”、“密盖息”。
发行价格:
24.34
{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":41.2,"timestamp":1766038135000,"preClose":41.72,"halted":0,"volume":1044100,"delay":0,"changeRate":-0.0125,"floatShares":158000000,"shares":159000000,"eps":0.3593,"marketStatus":"交易中","change":-0.52,"latestTime":"12-18 14:08:55","open":41.52,"high":41.96,"low":41.1,"amount":43202000,"amplitude":0.0206,"askPrice":41.21,"askSize":5,"bidPrice":41.2,"bidSize":19,"shortable":0,"etf":0,"ttmEps":0.3593,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766041200000},"marketStatusCode":2,"adr":0,"adjPreClose":41.72,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":45.89,"lowLimit":37.55,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":159010477,"isCdr":false,"pbRate":2.08,"roa":"--","peRate":114.667409,"roe":"4.04%","epsLYR":0.27,"committee":0.813084,"marketValue":6551000000,"turnoverRate":0.0066,"status":1,"floatMarketCap":6519000000},"requestUrl":"/m/hq/s/603590","defaultTab":"news","newsList":[{"id":"2591620673","title":"康辰药业拟取消监事会并修订公司章程,将召开股东大会审议多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2591620673","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591620673?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:22","pubTimestamp":1765844541,"startTime":"0","endTime":"0","summary":"中访网数据 北京康辰药业股份有限公司于2025年12月16日发布公告,将于2025年12月31日召开2025年第三次临时股东大会。本次会议将审议多项重要议案,核心内容包括公司治理结构的重大调整及董事会换届选举。 主要审议事项如下:第一,公司拟取消监事会,并相应修订《公司章程》。其中,关于取消监事会及修订《公司章程》、《股东会议事规则》、《董事会议事规则》的议案需以特别决议通过。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251216/31867657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2591164645","title":"康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591164645?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:05","pubTimestamp":1765800325,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)发布公告,近日,公司自主研发的KC1036片(简称“KC1036”),顺利完成“KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌临床试验(KC1036-COM-01)”首例受试者入组服药。KC1036是公司自主研发的化学药品1类创新药,公司拥有该产品的全球知识产权。KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。KC1036具有较强的VEGFR血管靶向,抑制肿瘤细胞生长;通过抑制AXL,可以改善宿主的抗肿瘤免疫应答,从而避免肿瘤的免疫逃逸。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","PD","BK4023","603590","BK0239","LU1169589451.USD"],"gpt_icon":0},{"id":"2588092119","title":"异动快报:康辰药业(603590)12月3日13点13分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2588092119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588092119?lang=zh_cn&edition=full","pubTime":"2025-12-03 13:15","pubTimestamp":1764738929,"startTime":"0","endTime":"0","summary":"证券之星12月3日盘中消息,13点13分康辰药业(603590)触及涨停板。其所属行业生物制品目前下跌。领涨股为康辰药业。该股为医药,化学原料药,创新药概念热股,当日医药概念上涨0.29%。12月2日的资金流向数据方面,主力资金净流出414.79万元,占总成交额7.63%,游资资金净流入391.5万元,占总成交额7.2%,散户资金净流入23.29万元,占总成交额0.43%。近5日资金流向一览见下表:康辰药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300016965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2586626809","title":"康辰药业(603590)披露召开2025年第三季度业绩说明会,11月26日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586626809","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586626809?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:27","pubTimestamp":1764167242,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘,康辰药业报收于43.83元,较前一交易日下跌1.28%,最新总市值为69.85亿元。公司近日发布公告称,北京康辰药业股份有限公司将于2025年12月04日16:00-17:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会,介绍公司2025年第三季度经营成果及财务状况。投资者可于2025年11月27日至12月3日16:00前通过上证路演中心或公司邮箱ir@konruns.cn提问,公司将在说明会上对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600039024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2582861639","title":"每周股票复盘:康辰药业(603590)董事减持3%股份,公司回购39.74万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861639","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861639?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:46","pubTimestamp":1762631172,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,康辰药业报收于45.8元,较上周的50.5元下跌9.31%。本周,康辰药业11月3日盘中最高价报50.76元。股本股东变化高管增减持2025年10月31日,公司董事刘建华减持公司股份53.12万股,占公司总股本的0.3333%。公司公告汇总康辰药业股东减持股份结果公告本次减持计划实施前,控股股东刘建华持有公司股份50,786,760股,占公司总股本的31.87%。本次减持后,刘建华持股数量为46,006,160股,持股比例为28.87%,实际减持情况与此前披露一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2581744282","title":"康辰药业已回购40万股 金额2016万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581744282","media":"财中社","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581744282?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:53","pubTimestamp":1762332780,"startTime":"0","endTime":"0","summary":"11月5日,康辰药业(603590)发布公告,截至2025年10月31日已回购40万股,占总股本的0.25%,回购资金总额为2016万元,回购价格区间为49.69元/股至51.4元/股。 2025年前三季度,康辰药业实现收入6.92亿元,归母净利润1.28亿元。(文章来源:财中社)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwiwtt4314955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2581794012","title":"太平洋:给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2581794012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581794012?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:55","pubTimestamp":1762304122,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚,张懿近期对康辰药业进行研究并发布了研究报告《康辰药业:血凝酶市场潜力较大,在研管线临床推进顺利》,给予康辰药业买入评级。2025年8月,KC1086的I期临床试验已完成首例受试者入组,预计2026年完成I期临床。最新盈利预测明细如下:该股最近90天内共有9家机构给出评级,买入评级8家,增持评级1家;过去90天内机构目标均价为66.81。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500005745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","601099"],"gpt_icon":0},{"id":"2580883017","title":"11月4日康辰药业跌6.45%,前海开源医疗健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580883017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580883017?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:28","pubTimestamp":1762244900,"startTime":"0","endTime":"0","summary":"证券之星消息,11月4日康辰药业跌6.45%创60日新低,收盘报45.87元,换手率2.54%,成交量4.02万手,成交额1.87亿元。重仓康辰药业的前十大公募基金请见下表:该股最近90天内共有9家机构给出评级,买入评级8家,增持评级1家;过去90天内机构目标均价为66.81。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共17家,其中持有数量最多的公募基金为前海开源基金的前海开源医疗健康A。该公募基金现任基金经理为范洁。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","159891","BK0239","150219"],"gpt_icon":0},{"id":"2580979602","title":"康辰药业:10月31日高管刘建华减持股份合计53.12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580979602","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580979602?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:02","pubTimestamp":1762171348,"startTime":"0","endTime":"0","summary":"证券之星消息,根据11月3日市场公开信息、上市公司公告及交易所披露数据整理,康辰药业最新董监高及相关人员股份变动情况:2025年10月31日公司董事刘建华共减持公司股份53.12万股,占公司总股本为0.3333%。康辰药业近半年内的董监高及核心技术人员增减持详情如下:康辰药业的高管列表及最新持股情况如下:该股最近90天内共有9家机构给出评级,买入评级8家,增持评级1家;过去90天内机构目标均价为66.81。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300031508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2580472381","title":"每周股票复盘:康辰药业(603590)三季报扣非净利增25.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580472381","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580472381?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:27","pubTimestamp":1762036030,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,康辰药业报收于50.5元,较上周的48.41元上涨4.32%。本周,康辰药业10月31日盘中最高价报50.76元。交易信息汇总10月31日康辰药业发生6笔大宗交易,合计成交2273.53万元,折价15.25%。业绩披露要点康辰药业2025年三季报显示,前三季度主营收入6.92亿元,同比上升7.1%;归母净利润1.28亿元,同比上升13.19%;扣非净利润1.33亿元,同比上升25.9%。公司公告汇总康辰药业发布2025年第三季度报告,主要财务数据显示营收稳步增长,扣非净利润增速显著。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2579109624","title":"康辰药业(603590)2025年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579109624","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579109624?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:19","pubTimestamp":1761862762,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期康辰药业发布2025年三季报。截至本报告期末,公司营业总收入6.92亿元,同比上升7.1%,归母净利润1.28亿元,同比上升13.19%。按单季度数据看,第三季度营业总收入2.31亿元,同比下降4.12%,第三季度归母净利润3683.4万元,同比上升9.06%。本报告期康辰药业盈利能力上升,毛利率同比增幅0.88%,净利率同比增幅1.52%。持有康辰药业最多的基金为前海开源医疗健康A,目前规模为5.46亿元,最新净值1.2692,较上一交易日上涨2.08%,近一年上涨38.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100007851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590"],"gpt_icon":0},{"id":"2579861301","title":"康辰药业(603590.SH)发布前三季度业绩,归母净利润1.28亿元,同比增长13.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579861301","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579861301?lang=zh_cn&edition=full","pubTime":"2025-10-30 00:41","pubTimestamp":1761756081,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)披露2025年第三季度报告,公司前三季度实现营收6.92亿元,同比增长7.10%;归母净利润1.28亿元,同比增长13.19%;扣非净利润1.33亿元,同比增长25.90%;基本每股收益0.81元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603590"],"gpt_icon":0},{"id":"2579920186","title":"康辰药业(603590)9月30日股东户数1.07万户,较上期增加7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579920186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579920186?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:19","pubTimestamp":1761729561,"startTime":"0","endTime":"0","summary":"证券之星消息,近日康辰药业披露,截至2025年9月30日公司股东户数为1.07万户,较6月30日增加716.0户,增幅为7.18%。在生物制品行业个股中,康辰药业股东户数低于行业平均水平,截至9月30日,生物制品行业平均股东户数为3.4万户。从股价来看,2025年6月30日至2025年9月30日,康辰药业区间涨幅为71.12%,在此期间股东户数增加716.0户,增幅为7.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900035469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2578507016","title":"每周股票复盘:康辰药业(603590)董事减持近千万股且回购首秀耗资1915万","url":"https://stock-news.laohu8.com/highlight/detail?id=2578507016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578507016?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:18","pubTimestamp":1761423491,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,康辰药业报收于48.41元,较上周的49.22元下跌1.65%。本周,康辰药业10月20日盘中最高价报52.58元。交易信息汇总10月24日,康辰药业发生1笔折价10.37%的大宗交易,合计成交203.93万元。股本股东变化2025年10月20日,公司董事刘建华减持191.19万股,占总股本1.1998%,当日收盘价为51.19元,期间股价上涨4.0%。刘建华个人持股比例由30.43%降至29.23%,公司控制权未发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2577878591","title":"10月24日康辰药业现1笔折价10.37%的大宗交易 合计成交203.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577878591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577878591?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:24","pubTimestamp":1761297865,"startTime":"0","endTime":"0","summary":"证券之星消息,10月24日康辰药业发生大宗交易,交易数据如下:大宗交易成交价格43.39元,相对当日收盘价折价10.37%,成交4.7万股,成交金额203.93万元,买方营业部为机构专用,卖方营业部为中国银河证券股份有限公司北京中关村大街证券营业部。近三个月该股共发生26笔大宗交易,合计成交2.66万手,折价成交26笔。截至2025年10月24日收盘,康辰药业报收于48.41元,上涨0.41%,换手率1.27%,成交量2.0万手,成交额9726.66万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400031258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2577615593","title":"康辰药业:10月20日高管刘建华减持股份合计191.19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577615593","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577615593?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:02","pubTimestamp":1761134556,"startTime":"0","endTime":"0","summary":"证券之星消息,根据10月22日市场公开信息、上市公司公告及交易所披露数据整理,康辰药业最新董监高及相关人员股份变动情况:2025年10月20日公司董事刘建华共减持公司股份191.19万股,占公司总股本为1.1998%。变动期间公司股价上涨4.0%,10月20日当日收盘报51.19元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200034174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2577733827","title":"康辰药业:10月17日高管刘建华减持股份合计102.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577733827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577733827?lang=zh_cn&edition=full","pubTime":"2025-10-21 20:02","pubTimestamp":1761048141,"startTime":"0","endTime":"0","summary":"证券之星消息,根据10月21日市场公开信息、上市公司公告及交易所披露数据整理,康辰药业最新董监高及相关人员股份变动情况:2025年10月17日公司董事刘建华共减持公司股份102.15万股,占公司总股本为0.641%。康辰药业近半年内的董监高及核心技术人员增减持详情如下:康辰药业的高管列表及最新持股情况如下:该股最近90天内共有9家机构给出评级,买入评级8家,增持评级1家;过去90天内机构目标均价为66.81。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100032896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2576683268","title":"10月20日康辰药业现16笔折价13.46%的大宗交易 合计成交4473.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576683268","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576683268?lang=zh_cn&edition=full","pubTime":"2025-10-20 17:20","pubTimestamp":1760952058,"startTime":"0","endTime":"0","summary":"证券之星消息,10月20日康辰药业发生大宗交易,交易数据如下:近三个月该股共发生25笔大宗交易,合计成交2.61万手,折价成交25笔。该股在过去半年内已有共计98.6万股限售解禁股上市,占公司总股本的0.62%。截至2025年10月20日收盘,康辰药业报收于51.19元,上涨4.0%,换手率3.82%,成交量6.05万手,成交额3.08亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000022058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2576049936","title":"每周股票复盘:康辰药业(603590)推5000万至1亿元回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2576049936","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576049936?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:38","pubTimestamp":1760816290,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘,康辰药业报收于49.22元,较上周的50.58元下跌2.69%。本周,康辰药业10月17日盘中最高价报54.86元。本周关注点公司公告汇总:康辰药业董事会通过5000万元至1亿元股份回购计划。交易信息汇总10月17日,康辰药业发生一笔1494.57万元的大宗交易。股本股东变化2025年10月17日,控股股东刘建华通过集中竞价和大宗交易方式合计减持康辰药业股份1,021,500股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2576038573","title":"10月17日康辰药业现1494.57万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2576038573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576038573?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:20","pubTimestamp":1760692824,"startTime":"0","endTime":"0","summary":"证券之星消息,10月17日康辰药业发生大宗交易,交易数据如下:大宗交易成交价格45.29元,相对当日收盘价折价7.98%,成交33万股,成交金额1494.57万元,买方营业部为东兴证券股份有限公司北京中关村大街证券营业部,卖方营业部为中国银河证券股份有限公司北京中关村大街证券营业部。近三个月该股共发生9笔大宗交易,合计成交1.6万手,折价成交9笔。截至2025年10月17日收盘,康辰药业报收于49.22元,下跌2.19%,换手率3.49%,成交量5.52万手,成交额2.85亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700027376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766038144037,"stockEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.0798},{"period":"3month","weight":-0.2678},{"period":"6month","weight":0.4104},{"period":"1year","weight":0.6422},{"period":"ytd","weight":0.8084}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10686人(较上一季度增加7.18%)","perCapita":"14806股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"15901万元","survey":" 北京康辰药业股份有限公司的主营业务是化学药品制剂制造。公司的主要产品是“苏灵”、“密盖息”。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}